JP2018506528A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018506528A5 JP2018506528A5 JP2017540056A JP2017540056A JP2018506528A5 JP 2018506528 A5 JP2018506528 A5 JP 2018506528A5 JP 2017540056 A JP2017540056 A JP 2017540056A JP 2017540056 A JP2017540056 A JP 2017540056A JP 2018506528 A5 JP2018506528 A5 JP 2018506528A5
- Authority
- JP
- Japan
- Prior art keywords
- individual
- osm
- optionally
- osmr
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1501480.6A GB201501480D0 (en) | 2015-01-29 | 2015-01-29 | Biomarker |
| GB1501480.6 | 2015-01-29 | ||
| GB201501511A GB201501511D0 (en) | 2015-01-29 | 2015-01-29 | Biomarker |
| GB1501511.8 | 2015-01-29 | ||
| GBGB1521446.3A GB201521446D0 (en) | 2015-12-04 | 2015-12-04 | Biomarker |
| GB1521446.3 | 2015-12-04 | ||
| PCT/GB2016/050185 WO2016120625A1 (en) | 2015-01-29 | 2016-01-28 | Biomarker |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018506528A JP2018506528A (ja) | 2018-03-08 |
| JP2018506528A5 true JP2018506528A5 (https=) | 2019-03-07 |
| JP6999417B2 JP6999417B2 (ja) | 2022-02-04 |
Family
ID=55299667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017540056A Active JP6999417B2 (ja) | 2015-01-29 | 2016-01-28 | Ｉｂｄにおける治療標的及びバイオマーカー |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10822406B2 (https=) |
| EP (2) | EP3974450A3 (https=) |
| JP (1) | JP6999417B2 (https=) |
| KR (1) | KR20170132143A (https=) |
| CN (1) | CN107530431B (https=) |
| AU (1) | AU2016210996B2 (https=) |
| MX (1) | MX2017009695A (https=) |
| WO (1) | WO2016120625A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201614627D0 (en) * | 2016-08-30 | 2016-10-12 | Glaxosmithkline Ip Dev Ltd | Antigen binding proteins |
| EP3554362A4 (en) * | 2016-12-14 | 2020-08-12 | Warren, Tracy | SYSTEM AND METHODS FOR DEVELOPING AND USING A MICROBIOME-BASED ACTION COMPONENT FOR PATIENT HEALTH |
| US11978543B2 (en) | 2016-12-14 | 2024-05-07 | Astarte Medical Partners Inc. | System and methods for developing and using a microbiome-based action component |
| IL326629A (en) * | 2018-04-25 | 2026-04-01 | Kiniksa Pharmaceuticals Ltd | Treatment of skin diseases or disorders through administration of anti-OSMR BETA antibody |
| US11779643B2 (en) * | 2019-08-28 | 2023-10-10 | Children's Hospital Medical Center | Methods and compositions for the treatment of an inflammatory bowel disease |
| WO2021039771A1 (ja) * | 2019-08-29 | 2021-03-04 | 国立大学法人東北大学 | 炎症性腸疾患の診断方法、診断プローブ及び診断キット |
| CN113699187B (zh) * | 2020-05-20 | 2023-08-08 | 中国科学院微生物研究所 | 一种肠易激综合征小鼠模型及其应用 |
| TWI904261B (zh) | 2020-10-19 | 2025-11-11 | 美商碩騰服務公司 | 犬及貓抑瘤素Ｍ受體β之抗體及其用途 |
| IL285031A (en) * | 2021-07-21 | 2023-02-01 | Yeda Res & Dev | Diagnosis of inflammatory bowel diseases |
| CN116377048B (zh) * | 2022-04-22 | 2024-05-07 | 广州市妇女儿童医疗中心 | S100a8/a9复合体在诊治先天性巨结肠中的应用 |
| TW202515615A (zh) * | 2023-09-01 | 2025-04-16 | 美商建南德克公司 | 治療發炎性腸病之方法 |
| WO2025153079A1 (en) * | 2024-01-19 | 2025-07-24 | Biomap (Suzhou) Intelligent Technology Limited | Method of treatment |
| CN119955922A (zh) * | 2025-01-15 | 2025-05-09 | 浙江大学 | 生物标志物在制备炎症性肠病筛查或亚型检测产品的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6531506B1 (en) | 1996-08-13 | 2003-03-11 | Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of hypertension |
| US6693130B2 (en) | 1999-02-18 | 2004-02-17 | Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of hypertension |
| US5958442A (en) | 1997-10-24 | 1999-09-28 | Bristol-Myers Squibb Company | Oncostatin M for treating inflammation |
| GB9806530D0 (en) * | 1998-03-26 | 1998-05-27 | Glaxo Group Ltd | Inflammatory mediator |
| US8563525B2 (en) | 2004-01-12 | 2013-10-22 | Natrogen Therapeutics International, Inc. | Methods of treating an inflammatory-related disease |
| EP1671642A1 (en) | 2004-12-15 | 2006-06-21 | Universite D'angers | Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof. |
| EP1846455A4 (en) | 2005-02-03 | 2010-02-17 | Raven Biotechnologies Inc | ANTIBODY TO THE ONKOSTATIN M RECEPTOR |
| WO2006133257A2 (en) | 2005-06-06 | 2006-12-14 | The Regents Of The University Of California | Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to reduce cardiomyopathy |
| WO2007133816A2 (en) | 2006-01-10 | 2007-11-22 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists |
| WO2008028044A2 (en) | 2006-08-30 | 2008-03-06 | Centocor, Inc. | Markers and methods for assessing and treating ulcerative colitis and related disorders using 66 gene panel |
| US20080293582A1 (en) | 2006-08-30 | 2008-11-27 | Xilin Li | Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using a 43 Gene Panel |
| CN102171365B (zh) | 2008-08-25 | 2014-01-29 | 森托科尔奥索生物科技公司 | 用于溃疡性结肠炎和相关疾病的抗tnf治疗的生物标记物 |
| AU2011308629A1 (en) | 2010-09-30 | 2013-05-23 | Evonik Corporation | Drug delivery blade and methods for delivering a drug depot to a target site |
| PH12013500703A1 (en) | 2010-10-13 | 2013-05-20 | Janssen Biotech Inc | Human oncostatin m antibodies and methods of use |
| AR083937A1 (es) * | 2010-11-23 | 2013-04-10 | Glaxo Group Ltd | Proteinas de union a antigenos |
| JP6214010B2 (ja) | 2012-05-11 | 2017-10-18 | 公立大学法人和歌山県立医科大学 | 抗オンコスタチンｍ受容体ベータ抗体 |
| CN105209643A (zh) | 2013-05-17 | 2015-12-30 | 豪夫迈·罗氏有限公司 | 用于诊断和治疗炎性肠病的方法 |
| SI3456743T1 (sl) | 2013-05-30 | 2022-01-31 | Kiniksa Pharmaceuticals, Ltd. | Proteini, ki vežejo antigen receptorja onkostatina M |
-
2016
- 2016-01-28 KR KR1020177024112A patent/KR20170132143A/ko not_active Withdrawn
- 2016-01-28 JP JP2017540056A patent/JP6999417B2/ja active Active
- 2016-01-28 MX MX2017009695A patent/MX2017009695A/es unknown
- 2016-01-28 US US15/547,154 patent/US10822406B2/en active Active
- 2016-01-28 CN CN201680015517.5A patent/CN107530431B/zh active Active
- 2016-01-28 EP EP21168214.1A patent/EP3974450A3/en not_active Withdrawn
- 2016-01-28 EP EP16702773.9A patent/EP3250599B1/en active Active
- 2016-01-28 WO PCT/GB2016/050185 patent/WO2016120625A1/en not_active Ceased
- 2016-01-28 AU AU2016210996A patent/AU2016210996B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018506528A5 (https=) | ||
| Liu et al. | Inflammatory bowel disease biomarkers | |
| Liew et al. | Endothelial glycocalyx damage in kidney disease correlates with uraemic toxins and endothelial dysfunction | |
| Baba et al. | Survival prediction for advanced cancer patients in the real world: A comparison of the Palliative Prognostic Score, Delirium-Palliative Prognostic Score, Palliative Prognostic Index and modified Prognosis in Palliative Care Study predictor model | |
| Atreya et al. | Biomarkers for personalizing IBD therapy: the quest continues | |
| Aoki et al. | Development and validation of a risk scoring system for severe acute lower gastrointestinal bleeding | |
| Judd et al. | Update of fecal markers of inflammation in inflammatory bowel disease | |
| Spassova et al. | Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma | |
| CN113348254A (zh) | 用于确定针对癌症患者的治疗的方法 | |
| Robinson et al. | Biomarkers to guide clinical therapeutics in rheumatology? | |
| Roodenrijs et al. | Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis | |
| ES3041639T3 (en) | Biomarkers and methods for assessing psoriatic arthritis disease activity | |
| Niki et al. | Clinical significance of cartilage biomarkers for monitoring structural joint damage in rheumatoid arthritis patients treated with anti-TNF therapy | |
| JP2021518432A5 (https=) | ||
| Toiyama et al. | Evaluation of preoperative C-reactive protein aids in predicting poor survival in patients with curative colorectal cancer with poor lymph node assessment | |
| JP2018504584A (ja) | 過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法 | |
| Morris et al. | Biomarker-based models outperform patient-reported scores in predicting endoscopic inflammatory disease activity | |
| Gu et al. | Identification of RGS1 as a candidate biomarker for undifferentiated spondylarthritis by genome‐wide expression profiling and real‐time polymerase chain reaction | |
| Dolinger et al. | Early intestinal ultrasound response to biologic therapy predicts endoscopic remission in children with ileal Crohn’s disease: results from the prospective super sonic study | |
| Lin et al. | Understanding anti‐TNF treatment failure: does serum triiodothyronine‐to‐thyroxine (T3/T4) ratio predict therapeutic outcome to anti‐TNF therapies in biologic‐naïve patients with active luminal Crohn's disease? | |
| Liu et al. | Identification and immunological characterization of lipid metabolism-related molecular clusters in nonalcoholic fatty liver disease | |
| Chaemsupaphan et al. | Comprehensive care of ulcerative colitis: new treatment strategies | |
| US11199534B2 (en) | Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis | |
| Shimoyama et al. | Faecal calprotectin level for assessing endoscopic activity and predicting future clinical course in patients with moderately active ulcerative colitis undergoing granulomonocytapheresis: a prospective cohort study | |
| Chernoff et al. | Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scores |